Register for our free email digests:
Latest From Monopar Therapeutics LLC
Monopar Therapeutics LLC is focusing on developing treatments for hard-to-treat cancer subtypes. Its lead program, huATN-658, is a humanized monoclonal antibody that targets the urokinase plasminogen activator receptor (uPAR). A protein receptor, uPAR is found on certain cancer cells, but it has little to no expression on healthy tissue; it is linked with tumor cell survival, its expression increases in high-grade and metastatic disease and it is correlated with a worse prognosis in several cancers.
This Month's Profile Group, Parkinson’s Disease: Start-Ups Seek Breakthroughs And Money, features profiles of MentiNova, Parkure and Prexton Therapeutics. Plus these Start-Ups Across Health Care: Apifix, Monopar Therapeutics, MitoGenetics, Preora Diagnostics, and Viking Therapeutics.
- Radiofrequency Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- Gynecological, Urological
- Renal System
- North America
- Parent & Subsidiaries
- NxThera Inc.
- Senior Management
J. Robert Paulson, CEO
Carmen Bringgold, SVP, Commercialization & CFO
Maximillian D Fiore, Chief Dev. & Operations Officer
Michael Hoey, CTO
Kari Cierzan, Dir., Mktg.
- Contact Info
Phone: (763) 515-0404
7351 Kirkwood Lane North
Maple Grove, MN 55369
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.